Exact Sciences Corporation (NASDAQ:EXAS) SVP D Scott Coward sold 29,115 shares of Exact Sciences Corporation stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $47.16, for a total value of $1,373,063.40. Following the sale, the senior vice president now directly owns 64,991 shares in the company, valued at $3,064,975.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Shares of Exact Sciences Corporation (NASDAQ:EXAS) traded up 2.46% during mid-day trading on Tuesday, reaching $49.12. 2,992,065 shares of the company’s stock were exchanged. Exact Sciences Corporation has a one year low of $13.05 and a one year high of $50.65. The company has a 50 day moving average price of $42.56 and a 200-day moving average price of $34.76. The stock’s market cap is $5.85 billion.

Exact Sciences Corporation (NASDAQ:EXAS) last issued its earnings results on Tuesday, July 25th. The medical research company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.10. Exact Sciences Corporation had a negative net margin of 83.08% and a negative return on equity of 36.36%. The company had revenue of $57.65 million for the quarter, compared to the consensus estimate of $47.73 million. On average, analysts predict that Exact Sciences Corporation will post ($1.18) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Insider Selling: Exact Sciences Corporation (EXAS) SVP Sells 29,115 Shares of Stock” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/03/insider-selling-exact-sciences-corporation-exas-svp-sells-29115-shares-of-stock.html.

EXAS has been the subject of several recent research reports. Canaccord Genuity reaffirmed a “buy” rating and issued a $60.00 price objective (up previously from $45.00) on shares of Exact Sciences Corporation in a research note on Tuesday. Zacks Investment Research upgraded shares of Exact Sciences Corporation from a “hold” rating to a “buy” rating and set a $51.00 target price on the stock in a research report on Tuesday, September 26th. Leerink Swann reiterated an “outperform” rating and set a $50.00 target price (up from $45.00) on shares of Exact Sciences Corporation in a research report on Thursday, September 21st. BidaskClub raised shares of Exact Sciences Corporation from a “buy” rating to a “strong-buy” rating in a report on Friday, August 25th. Finally, BTIG Research reissued a “buy” rating and set a $45.00 target price (up from $35.00) on shares of Exact Sciences Corporation in a report on Monday, July 17th. Five investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $43.11.

Institutional investors have recently made changes to their positions in the business. Russell Investments Group Ltd. increased its position in shares of Exact Sciences Corporation by 113.5% in the first quarter. Russell Investments Group Ltd. now owns 119,482 shares of the medical research company’s stock valued at $2,822,000 after acquiring an additional 63,519 shares during the period. Wells Fargo & Company MN boosted its holdings in shares of Exact Sciences Corporation by 48.4% during the first quarter. Wells Fargo & Company MN now owns 312,432 shares of the medical research company’s stock worth $7,380,000 after purchasing an additional 101,841 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Exact Sciences Corporation by 32.4% during the first quarter. Bank of New York Mellon Corp now owns 646,758 shares of the medical research company’s stock worth $15,275,000 after purchasing an additional 158,347 shares during the period. Swiss National Bank boosted its holdings in shares of Exact Sciences Corporation by 1.0% during the first quarter. Swiss National Bank now owns 179,319 shares of the medical research company’s stock worth $4,236,000 after purchasing an additional 1,700 shares during the period. Finally, Ameriprise Financial Inc. boosted its holdings in shares of Exact Sciences Corporation by 11.0% during the first quarter. Ameriprise Financial Inc. now owns 240,030 shares of the medical research company’s stock worth $5,683,000 after purchasing an additional 23,804 shares during the period. 85.23% of the stock is currently owned by institutional investors and hedge funds.

About Exact Sciences Corporation

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Insider Buying and Selling by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.